These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 15772898

  • 21. Short-term effects of metformin in type 2 diabetes.
    Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA.
    Diabetes Obes Metab; 2007 Jul; 9(4):483-9. PubMed ID: 17587390
    [Abstract] [Full Text] [Related]

  • 22. Importance of postprandial glucose control.
    Bell DS.
    South Med J; 2001 Aug; 94(8):804-9. PubMed ID: 11549192
    [Abstract] [Full Text] [Related]

  • 23. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects.
    Formoso G, De Filippis EA, Michetti N, Di Fulvio P, Pandolfi A, Bucciarelli T, Ciabattoni G, Nicolucci A, Davì G, Consoli A.
    Diabetes Metab Res Rev; 2008 Aug; 24(3):231-7. PubMed ID: 17966969
    [Abstract] [Full Text] [Related]

  • 24. Total and acylated ghrelin levels in type 2 diabetic patients: similar levels observed after treatment with metformin, pioglitazone or diet therapy.
    Kiyici S, Ersoy C, Oz Gul O, Sarandol E, Demirci M, Tuncel E, Sigirli D, Erturk E, Imamoglu S.
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):386-90. PubMed ID: 19629933
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B, Pacini G, Tura A, Foley JE, Schweizer A.
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
    Chugh SN, Dhawan R, Kishore K, Sharma A, Chugh K.
    J Assoc Physicians India; 2001 Aug; 49():803-7. PubMed ID: 11837468
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Normal insulin response to short-term intense exercise is abolished in Type 2 diabetic patients treated with gliclazide.
    Szewieczek J, Dulawa J, Strzałkowska D, Batko-Szwaczka A, Hornik B.
    J Diabetes Complications; 2009 Aug; 23(6):380-6. PubMed ID: 18394931
    [Abstract] [Full Text] [Related]

  • 31. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, QUARTET Study Group.
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
    Seufert J.
    Curr Med Res Opin; 2006 Apr; 22 Suppl 2():S39-48. PubMed ID: 16914074
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
    James AP, Watts GF, Mamo JC.
    Diabetes Obes Metab; 2005 Jul; 7(4):381-9. PubMed ID: 15955124
    [Abstract] [Full Text] [Related]

  • 36. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP.
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [Abstract] [Full Text] [Related]

  • 39. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.